Minerva Neurosciences, Inc. announced the appointment of Michael Davidson, M.D., as chief medical officer effective December 19, 2016. His responsibilities will include the strategic development and clinical advancement of the company’s products, which target schizophrenia (MIN-101), insomnia (MIN-202), major depressive disorder (MIN-117) and Parkinson’s disease (MIN-301). Dr. Davidson brings to Minerva significant experience in the research and development of drugs to treat diseases of the central nervous system. He is currently professor of psychiatry at the Sackler School of Medicine, Tel Aviv University.